Objective: To investigate the clinical effect of ambroxol hydrochloride in the treatment of chronic obstructive pulmonary disease complicated with pulmonary infection. Methods: From February 2019 to February 2020,300 patients with chronic obstructive pulmonary disease and pulmonary infection were selected, The observation group was treated with ambroxol hydrochloride (150 cases), routine treatment in the control group (150). The clinical curative effect, the incidence of adverse reactions, the time of disappearance of clinical symptoms and signs, and the quality of life were compared and analyzed. Results：97.33% of clinical efficacy in observation group was higher than 85.33% in control group, The incidence of adverse reactions was 6.67% lower than 7.33% in the control group, but not statistically significant (P>0.05); Chest tightness and temperature recovery in the observation group, And lung rales, cough disappeared time shorter than the control group (P<0.05); Compared to the control group, All the quality of life scores in the observation group were higher (P<0.05). Conclusion: For patients with chronic obstructive pulmonary disease complicated with pulmonary infection, With ambroxol hydrochloride, Safe and effective, Can achieve remarkable therapeutic effect, No adverse reactions, Shorten chest tightness recovery, lung rales and cough loss, It has clinical application value.

 Application of RDW combined with cTnI in the diagnosis of myocardial injury in patients with severe pneumonia[J]. 中国当代医药, 2020, 27(36): 56-59.